Predicted protein targets (top 5)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.34 |
| ▸ | PKM | P14618 | 1/20 | 0.34 |
| ▸ | ESR2 | Q92731 | 2/20 | 0.32 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.31 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL17706160 | 1.00 | KDM4E (0.34) | KDM4EPKMESR2CYP2C9CYP2C19 | |
| SCHEMBL3012888 | 1.00 | KDM4E (0.34) | KDM4EPKMESR2CYP2C9CYP2C19 | |
| SCHEMBL21134592 | 0.80 | SLC6A4 (0.33) | KDM4EPKMESR2 | |
| SCHEMBL7732887 | 0.80 | SLC6A4 (0.33) | KDM4EPKMESR2 | |
| SCHEMBL21134598 | 0.80 | SLC6A4 (0.33) | KDM4EPKMESR2 | |
| SCHEMBL3748819 | 0.79 | ESR2 (0.50) | KDM4EPKMESR2CYP2C9CYP2C19 | |
| SCHEMBL18595246 | 0.79 | SHBG (0.36) | — | |
| SCHEMBL760606 | 0.79 | SHBG (0.36) | — | |
| SCHEMBL12424446 | 0.79 | ESR2 (0.50) | KDM4EPKMESR2CYP2C9CYP2C19 | |
| SCHEMBL12385989 | 0.79 | ESR2 (0.50) | KDM4EPKMESR2CYP2C9CYP2C19 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2016100281-A1 | INDOLE AND AZAINDOLES DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-06-23 | — | — | WO | disclosed |
| US-20160168090-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | MERCK PATENT GMBH (DE) | 2016-06-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160168090-A1 | NOVEL INDOLE DERIVATIVES AND THEIR USE IN NEURODEGENERATIVE DISEASES | P2RX3, P2RX7, P2RX2 | KDM4E 2549/4885PKM 1812/4885ESR2 2091/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.